Pharmacological properties of KRN2391, a novel vasodilator of the nitrate-potassium channel opener hybrid type.
1. The pharmacological properties of KRN2391 in animal experiments are reviewed. 2. The vasodilating mechanism of KRN2391 is based on both a nitrate action and a K channel opening action, and whether KRN2391 acts as a nitrate and/or a K channel opener depends on the type and the segment of blood vessels. 3. KRN2391 causes a preferential increase in coronary blood flow in anesthetized dogs. 4. KRN2391 produces an increase in oxygen supply to the heart and a decrease in myocardial oxygen consumption in anesthetized dogs. 5. KRN2391 shows antiangial effects in various anginal models of rats and cardioprotective effects in perfused rat hearts. 6. KRN2391 does not develop self-tolerance or cross-tolerance between KRN2391 and other nitrates in coronary dilating and vasodepressor effects. 7. The pharmacological properties of KRN2391 are thought to be beneficial for the treatment of patients with ischemic heart disease.
Ogawa
N
N
Pharmaceutical Research Laboratory, Kirin Brewery Co. Ltd. Gunma, Japan.
D000787:Angina Pectoris / Q000188:drug therapy*; D000818:Animals; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D015221:Potassium Channels / Q000187:drug effects*; D011725:Pyridines / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D015221:Potassium Channels; D011725:Pyridines; D014665:Vasodilator Agents; C070492:N-cyano-N'-(2-nitroxyethyl)-3-pyridinecarboximidamide methanesulfonate